TRACON Pharmaceuticals, Inc. (TCON) financial statements (2021 and earlier)

Company profile

Business Address 4350 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1639354452
Cash and cash equivalents1625293641
Short-term investments 145911
Other undisclosed cash, cash equivalents, and short-term investments(0)(0)0(0)0
Other undisclosed current assets12211
Total current assets:1741364653
Noncurrent Assets
Property, plant and equipment00000
Other noncurrent assets    0
Other undisclosed noncurrent assets1    
Total noncurrent assets:10000
TOTAL ASSETS:1841364654
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11121
Employee-related liabilities11121
Debt31301
Deferred revenue and credits113
Other undisclosed current liabilities811778
Total current liabilities:1213121014
Noncurrent Liabilities
Long-term debt and lease obligation35577
Long-term debt, excluding current maturities35577
Liabilities, other than long-term debt10301
Deferred revenue and credits2  
Accounts payable and accrued liabilities    1
Other liabilities1000 
Total noncurrent liabilities:46778
Total liabilities:1519191723
Stockholders' equity
Stockholders' equity attributable to parent321172831
Common stock00000
Additional paid in capital16516112211490
Accumulated deficit(162)(140)(105)(86)(59)
Total stockholders' equity:321172831
TOTAL LIABILITIES AND EQUITY:1841364654

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net938
Gross profit: 3938
Operating expenses(22)(38)(27)(29)(31)
Operating loss:(22)(35)(18)(26)(23)
Nonoperating expense(0)(0)(1)(1)(1)
Net loss attributable to parent:(23)(35)(19)(27)(24)
Preferred stock dividends and other adjustments    (0)
Net loss available to common stockholders, diluted:(23)(35)(19)(27)(24)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(23)(35)(19)(27)(24)
Comprehensive loss, net of tax, attributable to parent:(23)(35)(19)(27)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: